Article Details
Retrieved on: 2018-02-14 18:18:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>The institutional investor held 20,400 shares of the health care company at the end of 2017Q3, valued at $925,000, up from 10,000 at the end of the previous reported quarter. <b>Benchmark Capital</b> Advisors who had been investing in Sarepta Therapeutics I Com for a number of months, seems to be bullish ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here